Ampersand Biomedicines
↗Boston, MA, USA
Ampersand Biomedicines is a biotechnology company focused on developing 'smarter' biologic medicines, termed AND-Body™ Therapeutics. The company utilizes its proprietary, computationally powered Address, Navigate, Determine (AND)™ Platform to identify unique cell surface features ('addresses') to localize therapeutics specifically to diseased tissue, aiming to maximize efficacy while minimizing on-target, off-tissue toxicity.
Founded in 2021 by Flagship Pioneering, the company is advancing a pipeline of programmable medicines across therapeutic areas including immuno-oncology, immuno-inflammation, and obesity. Ampersand operates as a multi-product platform company, leveraging strategic partnerships with major pharmaceutical entities to accelerate its drug discovery and development efforts.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$115M
Investors:Flagship Pioneering, Eli Lilly & Company
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Biologics, Bispecific antibodies
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pfizer (metabolic pathways/programmable medicines), Pioneering Medicines (discovery program for obesity)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Jason Gardner - CEO and Director
Scientific Founders:Noubar Afeyan, Avak Kahvejian, Yann Echelard, Raffi Afeyan, Charlotte Nicod, Nick Plugis
Board Members:Elizabeth Mily
LINKS
Website:ampersand.bio
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ampersand Biomedicines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ampersand Biomedicines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.